SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2019

SUMMARY OF ACCOUNTING POLICIES

Schedule of operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Three Month Period Ended:
	December 31,		December 31,
	2019		2018
Research and development services (over-time)	$	366,834	$	473,178
Product and authentication services (point-in-time):
Supply chain		18,674		250,098
Asset marking		108,572		161,046
Large scale DNA production		139,439		—
Total	$	633,519	$	884,322

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		December 31,		$
	Balance sheet classification	2019		2019		change
Contract liabilities	Deferred revenue	$	628,993	$	455,051	$	173,942

Schedule of anti-dilutive securities not included computation of net loss per share

	2019	2018
Warrants	2,692,798	462,713
Stock options	220,241	154,430
Secured convertible notes	70,963	101,852
	2,984,002	718,995